F/M Investments’s Travere Therapeutics TVTX Stock Holding History

F/M Investments’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.7M	Buy	187,574 +22,584	+14%	+$1M	0.54%	37
2026 Q1	$4.9M	Sell	164,990 -3,426	-2%	-$102K	0.33%	66
2025 Q4	$6.44M	Sell	168,416 -27,658	-14%	-$899K	0.24%	102
2025 Q3	$4.69M	Buy	196,074 +8,340	+4%	+$157K	0.18%	138
2025 Q2	$2.78M	Buy	187,734 +40,269	+27%	+$667K	0.1%	199
2025 Q1	$2.64M	Buy	147,465 +36,307	+33%	+$737K	0.11%	191
2024 Q4	$1.94M	Buy	+111,158	New	+$1.97M	0.07%	233

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

F/M Investments's TVTX Position: Q2 2026 in Review

F/M Investments increased its Travere Therapeutics (TVTX) stake by 14% in Q2 2026, buying an estimated $1M and bringing the position to 187,574 shares worth $10.7M. The position accounts for 0.54% of the portfolio, ranked #37.

F/M Investments first reported a position in TVTX in Q4 2024 and has held it in 7 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

F/M Investments held 187,574 shares of Travere Therapeutics worth $10.7M as of Q2 2026.
F/M Investments bought 22,584 Travere Therapeutics shares in Q2 2026, an estimated $1M.
Travere Therapeutics made up 0.54% of F/M Investments's portfolio in Q2 2026, its #37 holding.
F/M Investments first reported a position in Travere Therapeutics in Q4 2024 and has held it in 7 quarters since.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on F/M Investments's 13F filing for Q2 2026, filed 5 Aug 2026.